Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)
December 29 2020 - 05:25PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a‑16 OR
15d‑16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
FOR THE MONTH OF DECEMBER 2020

COMMISSION FILE NUMBER 001-39081
BioNTech SE
(Translation of
registrant’s name into English)
An der Goldgrube 12
D-55131 Mainz
Germany
+49 6131-9084-0
(Address of
principal executive offices)

Indicate by check mark whether the registrant files or will file
annual reports under cover Form 20‑F or Form 40‑F: Form 20‑F
☒ Form 40‑F
☐
Indicate by check mark if the registrant is submitting the Form 6‑K
in paper as permitted by Regulation S‑T Rule 101(b)(1):
☐
Indicate by check mark if the registrant is submitting the Form 6‑K
in paper as permitted by Regulation S‑T Rule 101(b)(7): ☐
DOCUMENTS INCLUDED
AS PART OF THIS FORM 6-K
On December 29, 2020, BioNTech SE (the “Company”) and Pfizer Inc.
announced today that they will supply an additional 100 million
doses of COMIRNATY®, the
companies’ COVID-19 Vaccine, to the 27 European Union (EU) member
states in 2021. The press release is attached hereto as Exhibit
99.1.
SIGNATURE
Pursuant to the requirements of the Exchange Act, the registrant
has duly caused this report to be signed on its behalf by the
undersigned, thereunto duly authorized.
|
|
|
|
BioNTech SE
|
|
|
|
|
|
|
|
By:
|
/s/ Dr. Sierk Poetting
|
|
|
Name: Dr. Sierk Poetting
|
|
|
Title: Chief Financial Officer
|
Date: December 29, 2020
EXHIBIT
INDEX